Ixabepilone

Generic Name
Ixabepilone
Brand Names
Ixempra
Drug Type
Small Molecule
Chemical Formula
C27H42N2O5S
CAS Number
219989-84-1
Unique Ingredient Identifier
K27005NP0A
Background

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...

Indication

用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。

Associated Conditions
Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
Interventions
Drug: Ixabepilone
Drug: Capecitabine
First Posted Date
2007-12-05
Last Posted Date
2016-03-10
Lead Sponsor
R-Pharm
Target Recruit Count
9
Registration Number
NCT00568022
Locations
🇯🇵

Local Institution, Osaka, Japan

A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer

First Posted Date
2007-06-25
Last Posted Date
2016-03-10
Lead Sponsor
R-Pharm
Target Recruit Count
50
Registration Number
NCT00490646
Locations
🇹🇷

Local Institution, Izmir, Turkey

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

First Posted Date
2007-04-03
Last Posted Date
2016-02-24
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
384
Registration Number
NCT00455533
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Florida Cancer Research Institute, Davie, Florida, United States

🇺🇸

Albert Einstein Cancer Center, Bronx, New York, United States

and more 8 locations

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

First Posted Date
2006-10-02
Last Posted Date
2016-03-10
Lead Sponsor
R-Pharm
Target Recruit Count
58
Registration Number
NCT00383149
Locations
🇺🇸

Georgetn Univ Lombardi Can Ctr, Washington, District of Columbia, United States

🇺🇸

Ellis Fischel Cancer Center, Columbia, Missouri, United States

🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 6 locations

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

First Posted Date
2006-05-31
Last Posted Date
2017-10-31
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
100
Registration Number
NCT00331344
Locations
🇺🇸

University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Ixabepilone in Treating Young Patients With Refractory Solid Tumors

First Posted Date
2006-05-31
Last Posted Date
2014-11-14
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
120
Registration Number
NCT00331643
Locations
🇺🇸

Children's Oncology Group, Arcadia, California, United States

Phase I Combination w/ Epirubicin

Phase 1
Completed
Conditions
Metastatic Breast Cancer
Interventions
Drug: Ixabepilone
Drug: Epirubicin
First Posted Date
2006-05-05
Last Posted Date
2016-03-10
Lead Sponsor
R-Pharm
Target Recruit Count
42
Registration Number
NCT00322374
Locations
🇮🇹

Local Institution, Milano, Italy

Ixabepilone Administered as an Enteric Coated Formulation.

Phase 1
Completed
Conditions
Cancer
Interventions
Drug: Ixabepilone
First Posted Date
2006-03-31
Last Posted Date
2017-01-30
Lead Sponsor
R-Pharm
Target Recruit Count
30
Registration Number
NCT00309049
Locations
🇺🇸

Local Institution, Detroit, Michigan, United States

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

First Posted Date
2005-09-21
Last Posted Date
2020-11-02
Lead Sponsor
R-Pharm
Target Recruit Count
19
Registration Number
NCT00207090
Locations
🇺🇸

The Cleveland Clinic Foundation, Cleveland, Ohio, United States

Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies

First Posted Date
2005-09-21
Last Posted Date
2017-01-30
Lead Sponsor
R-Pharm
Target Recruit Count
25
Registration Number
NCT00207129
Locations
🇺🇸

Local Institution, San Antonio, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy